Tedisamil

Drug Profile

Tedisamil

Alternative Names: KC-8857

Latest Information Update: 15 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Solvay
  • Class Class III antiarrhythmics; Cyclopropanes; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Atrial fibrillation; Atrial flutter
  • Discontinued Angina pectoris; Ischaemic heart disorders

Most Recent Events

  • 15 Jun 2015 No recent reports on development identified - Registered for Atrial fibrillation in Spain and United Kingdom (IV)
  • 15 Jun 2015 No recent reports on development identified - Registered for Atrial flutter in Spain and United Kingdom (IV)
  • 26 Mar 2009 Tedisamil is available for licensing in Europe (http://www.solvay.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top